Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

NKX3.1 as a marker of prostatic origin in metastatic tumors.

Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM.

Am J Surg Pathol. 2010 Aug;34(8):1097-105. doi: 10.1097/PAS.0b013e3181e6cbf3.

2.

Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.

Kim J, Roh M, Abdulkadir SA.

BMC Cancer. 2010 Jun 1;10:248. doi: 10.1186/1471-2407-10-248.

3.

ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.

Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV, Carbone GM.

PLoS One. 2010 May 10;5(5):e10547. doi: 10.1371/journal.pone.0010547.

4.

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM.

Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018.

5.

MYC as a regulator of ribosome biogenesis and protein synthesis.

van Riggelen J, Yetil A, Felsher DW.

Nat Rev Cancer. 2010 Apr;10(4):301-9. doi: 10.1038/nrc2819. Review.

PMID:
20332779
6.

Pim1 regulates androgen-dependent survival signaling in prostate cancer cells.

van der Poel HG, Zevenhoven J, Bergman AM.

Urol Int. 2010;84(2):212-20. doi: 10.1159/000277601. Epub 2010 Mar 4.

PMID:
20215828
7.

MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.

Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, Lotz MT, Yegnasubramanian S, Nelson WG, Dang CV, Xu M, Anele U, Koh CM, Bieberich CJ, De Marzo AM.

PLoS One. 2010 Feb 25;5(2):e9427. doi: 10.1371/journal.pone.0009427.

8.

1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Washington MN, Weigel NL.

Endocrinology. 2010 Apr;151(4):1409-17. doi: 10.1210/en.2009-0991. Epub 2010 Feb 10.

9.

Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.

Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, Abdulkadir SA.

Oncogene. 2010 Apr 29;29(17):2477-87. doi: 10.1038/onc.2010.10. Epub 2010 Feb 8.

10.

Long-range enhancers on 8q24 regulate c-Myc.

Sotelo J, Esposito D, Duhagon MA, Banfield K, Mehalko J, Liao H, Stephens RM, Harris TJ, Munroe DJ, Wu X.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3001-5. doi: 10.1073/pnas.0906067107. Epub 2010 Jan 26.

11.
12.

Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.

Nandana S, Ellwood-Yen K, Sawyers C, Wills M, Weidow B, Case T, Vasioukhin V, Matusik R.

Prostate. 2010 May 1;70(6):591-600. doi: 10.1002/pros.21093.

13.

Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model.

Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H.

Cancer Res. 2009 Nov 15;69(22):8555-62. doi: 10.1158/0008-5472.CAN-08-4673. Epub 2009 Nov 3.

14.

Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate.

Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y, Zheng P.

Cancer Cell. 2009 Oct 6;16(4):336-46. doi: 10.1016/j.ccr.2009.08.016.

15.

Multiple loci on 8q24 associated with prostate cancer susceptibility.

Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Sawyer E, Lophatananon A; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, Donovan JL, Hamdy FC, Neal DE, Eeles RA, Easton DF.

Nat Genet. 2009 Oct;41(10):1058-60. doi: 10.1038/ng.452. Epub 2009 Sep 20.

PMID:
19767752
16.

A luminal epithelial stem cell that is a cell of origin for prostate cancer.

Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM.

Nature. 2009 Sep 24;461(7263):495-500. doi: 10.1038/nature08361. Epub 2009 Sep 9.

17.

Functional enhancers at the gene-poor 8q24 cancer-linked locus.

Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA.

PLoS Genet. 2009 Aug;5(8):e1000597. doi: 10.1371/journal.pgen.1000597. Epub 2009 Aug 14.

18.

ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.

Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON.

Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12465-70. doi: 10.1073/pnas.0905931106. Epub 2009 Jul 10.

19.

Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.

Kim J, Eltoum IE, Roh M, Wang J, Abdulkadir SA.

PLoS Genet. 2009 Jul;5(7):e1000542. doi: 10.1371/journal.pgen.1000542. Epub 2009 Jul 3.

20.

Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML.

Cancer Res. 2009 Jul 1;69(13):5568-74. doi: 10.1158/0008-5472.CAN-09-0387. Epub 2009 Jun 23.

Supplemental Content

Support Center